Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
NCT00327353 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 77
Last updated 2009-05-22
Summary
Effect of inhaled drugs administered as dry powder is not only dependent on drug efficacy but also on technical properties of the inhalers. Different inhalers have different internal resistances and therefore it is expected that patients with limited airflow may have different exposure rates of drugs delivered from different devices
Conditions
Interventions
- DRUG
-
formoterol (TURBOHALER)
- DRUG
-
Salmeterol (DISKUS)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials, MD · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
Countries
- Germany
Study Locations
More Related Trials
-
Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
NCT00685529 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Pilot Study on Budesonide/Formoterol
NCT01457716 ·Status: COMPLETED ·Phase: NA
-
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics
NCT00364442 ·Status: COMPLETED ·Phase: PHASE1
-
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
NCT02157935 ·Status: COMPLETED ·Phase: PHASE3
-
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00685841 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Particle Size in Small Airways Dysfunction
NCT01892787 ·Status: COMPLETED ·Phase: PHASE4
-
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
NCT00064402 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients
NCT01344655 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
NCT04078126 ·Status: COMPLETED ·Phase: PHASE3
-
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239421 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
NCT03590379 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus
NCT03060044 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
NCT00830102 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50
NCT03562923 ·Status: UNKNOWN ·Phase: PHASE3
-
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
NCT03888131 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
NCT01393145 ·Status: WITHDRAWN ·Phase: PHASE3
-
Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.
NCT01329276 ·Status: COMPLETED ·Phase: PHASE4
-
Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product
NCT00291382 ·Status: COMPLETED ·Phase: PHASE4
-
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
NCT00742248 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction
NCT01033669 ·Status: COMPLETED
-
Comparison Between Symbicort® and Prednisolone in COPD
NCT00259779 ·Status: COMPLETED ·Phase: PHASE3
-
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
NCT03197818 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
NCT00476073 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00064415 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
NCT00206167 ·Status: COMPLETED ·Phase: PHASE3